Thymoquinone attenuates cyclophosphamide-induced pulmonary injury in rats

Inflammopharmacology

Volumn 21, Issue 6, 2013, Pages 427-435

  Suddek, Ghada M ^a   Ashry, Nora A ^a   Gameil, Nariman M ^a  

^a MANSOURA UNIVERSITY   (Egypt)

Author keywords

Anti inflammatory; Antioxidant; Cyclophosphamide; Lung; Rats; Thymoquinone; Tumor necrosis factor

Indexed keywords

GLUTATHIONE; LACTATE DEHYDROGENASE; LIPID PEROXIDE; THYMOQUINONE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENUATION; BODY WEIGHT; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; HISTOPATHOLOGY; LIPID PEROXIDATION; LUNG HOMOGENATE; LUNG INJURY; LUNG WEIGHT; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTECTION; PROTEIN BLOOD LEVEL; RAT; TREATMENT DURATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTIOXIDANTS; BENZOQUINONES; BIOLOGICAL MARKERS; CYCLOPHOSPHAMIDE; GLUTATHIONE; INJECTIONS, INTRAPERITONEAL; LIPID PEROXIDATION; LIPID PEROXIDES; LUNG; LUNG DISEASES; MALE; OXIDATIVE STRESS; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84888361525     PISSN: 09254692     EISSN: 15685608     Source Type: Journal    
DOI: 10.1007/s10787-012-0160-6     Document Type: Article

References (49)

1. Alenzi FQ, El-Bolkiny Yel-S, Salem ML (2010) Protective effects of Nigella sativa oil and thymoquinone against toxicity induced by the anticancer drug cyclophosphamide. Br J Biomed Sci 67:20-28
2. Arslan N, Miller TR, Dehdashti F, Battafarano RJ, Siegel BA (2002a) Evaluation of response to neoadjuvant therapy by quantitative 2-deoxy-2 (18F), fluoro-d-glucose with positron emission tomography in patients with esophageal cancer. Mol Imaging Biol 4:301-310
3. Arslan SO, Zerin M, Vural H, Coskun A (2002b) The effect of melatonin on bleomycin-induced pulmonary fibrosis in rats. J Pineal Res 32:21-25
4. Badary OA (1999) Thymoquinone attenuates ifosfamide-induced Fanconi syndrome in rats and enhances its antitumor activity in mice. J Ethnopharmacol 67:135-142
5. Badary OA, Taha RA, Gamal el-Din AM, Abdel-Wahab MH (2003) Thymoquinone is a potent superoxide anion scavenger. Drug Chem Toxicol 26:87-98
6. Bowler RP, Nicks M, Warnick K, Crapo JD (2002) Role of extracellular superoxide dismutase in bleomycin-induced pulmonary fibrosis. Am J Physiol 282:L719-L726
7. Bukowski RM (1996) The need for cytoprotection. Eur J Cancer 32A(Suppl 4):S2-S4
8. Chehl N, Chipitsyna G, Gong Q, Yeo CJ, Arafat HA (2009) Anti-inflammatory effects of the Nigella sativa seed extract, thymoquinone, in pancreatic cancer cells. HPB (Oxford) 11:373-381
9. Daba MH, Abdel-Aziz AH, Moustafa AM, Al-Majed AA, Al-Shabanah OA, El-Kashef HA (2002) Effects of l-carnitine and Ginkgo Biloba extract (EGb 761) in experimental bleomycin-induced lung fibrosis. Pharmacol Res 45:461-467
10. Daniel WW (1991) Hypothesis testing. In: Biostatistics: a foundation for analysis in the health sciences, 5th edn. Wiley, New York
11. Das UB, Mallick M, Debnath JM, Ghosh D (2002) Protective effect of ascorbic acid on cyclophosphamide-induced testicular gametogenic and androgenic disorder in male rats. Asian J Androl 4:201-207
12. Donato ML, Aleman A, Champlin RE et al (2004) Analysis of 96 patients with advanced ovarian carcinoma treated with high-dose chemotherapy and autologous stem cell transplantation. Bone Marrow Transplant 33:1219-1224
13. El Gazzar M, El Mezayen R, Marecki JC, Nicolls MR, Canastar A, Dreskin SC (2006) Anti-inflammatory effect of thymoquinone in a mouse model of allergic lung inflammation. Int Immunopharmacol 6:1135-1142
14. El Gazzar M, El Mezayen R, Nicolls MR, Dreskin SC (2007) Thymoquinone attenuates proinflammatory responses in lipopolysaccharide-activated mast cells by modulating NF-kappaB nuclear transactivation. Biochim Biophys Acta 1770:556-564
15. Ellman GL (1959) Tissue sulfhydryl groups. Arch Biochem Biophys 82:70-77
16. El-Mahmoudy A, Shimizu Y, Shiina T, Matsuyama H, Nikami H, Takewaki T (2005) Macrophage-derived cytokine and nitric oxide profiles in type I and type II diabetes mellitus: effect of thymoquinone. Acta Diabetol 42:23-30
17. Fraiser LH, Kanekal S, Kehrer JP (1991) Cyclophosphamide toxicity; characterizing and avoiding the problem. Drug 42:781-795
18. Ghosh D, Das UB, Ghosh S, Mallick M, Debnath J (2002) Testicular gametogenic and steroidogenic activities in cyclophosphamide treated rat: a correlative study with testicular oxidative stress. Drug Chem Toxicol 25:281-292
19. Hales BF (1982) Comparison of the mutagenicity and teratogenicity of cyclophosphamide and its active metabolites, 4-hydroxycyclophosphamide, phosphoramide mustard, and acrolein. Cancer Res 42:3016-3021
20. Hirano A, Shimizu T, Watanabe O, Kinoshita J, Kimura K, Kamimura M, Domoto K, Aiba M, Ogawa K (2008) Epirubicin and cyclophosphamide followed by docetaxel as primary systemic chemotherapy in locally advanced breast cancer. Anticancer Res 28:4137-4142
21. Khattab MM, Nagi MN (2007) Thymoquinone supplementation attenuates hypertension and renal damage in nitric oxide deficient hypertensive rats. Phytother Res 21:410-414
22. Kim S, Tannock I, Sridhar S, Seki J, Bordeleau L (2012) Chemotherapy-induced infiltrative pneumonitis cases in breast cancer patients. J Oncol Pharm Pract 18:311-315
23. Kumar S, Dhankhar N, Kar V, Shrivastava M, Shrivastava S (2011) Myocardial injury provoked by cyclophosphamide, protective aspect of hesperidin in rats. Int J Res Pharm Biomed Sci 2:1288-1296
24. Levine MN, Pritchard KI, Bramwell VH, Shepherd LE, Tu D, Paul N (2005) Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. J Clin Oncol 23:5166-5170
25. Malik SW, Myers JL, DeRemee RA, Specks U (1996) Lung toxicity associated with cyclophosphamide use. Two distinct patterns. Am J Respir Crit Care Med 154:1851-1856
26. Manda K, Bhatia AL (2003) Prophylactic action of melatonin against cyclophosphamide-induced oxidative stress in mice. Cell Biol Toxicol 19:367-372
27. Marklund SL (1985) Superoxide dismutase isoenzymes in tissues and plasma from New Zealand black mice, nude mice and normal BALB/c mice. Mutat Res 148:129-134
28. McDiarmid MA, Iype PT, Kolodner K, Jacobson-Kram D, Strickland PT (1991) Evidence for acrolein-modified DNA in peripheral blood leucocytes of cancer patients treated with cyclophosphamide. Mutat Res 248:93-99
29. Nagi MN, Mansour MA (2000) Protective effect of thymoquinone against doxorubicin-induced cardiotoxicity in rats: a possible mechanism of protection. Pharmacol Res 41:283-289
30. Nagi MN, Al-Shabanah OA, Hafez MM, Sayed-Ahmed MM (2011) Thymoquinone supplementation attenuates cyclophosphamide-induced cardiotoxicity in rats. J Biochem Mol Toxicol 25:S135-S142
31. Nicolini A, Mancini P, Ferrari P et al (2004) Oral low-dose cyclophosphamide in metastatic hormone refractory prostate cancer (MHRPC). Biomed Pharmacother 58:447-450
32. O'Neil CA, Giri SN (1992) Effect of niacin on bleomycin-induced increases in myeloperoxidase, prolyl hydroxylase, and superoxide dismutase activities and collagen accumulation in the lungs of hamsters. J Biochem Toxicol 7:229-239
33. Ohkawa H, Ohishi N, Yagi K (1979) Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95:351-358
34. Patel JM (1987) Stimulation of cyclophosphamide-induced pulmonary microsomal lipid peroxidation by oxygen. Toxicology 45:79-91
35. Patel JM (1990) Metabolism and pulmonary toxicity of cyclophosphamide. Pharmacol Ther 47:137-146
36. Patel JM, Block ER (1985) Cyclophosphamide-induced depression of the antioxidant defense mechanisms of the lung. Exp Lung Res 8:153-165
37. Ragheb A, Attia A, Eldin WS, Elbarbry F, Gazarin S, Shoker A (2009) The protective effect of thymoquinone, an anti-oxidant and anti-inflammatory agent, against renal injury: a review. Saudi J Kidney Dis Transpl 20:741-752 Review
38. Rao R, Shammo JM, Enschede SH et al (2005) The combination of fludarabine, cyclophosphamide, and granulocyte-macrophage colony-stimulating factor in the treatment of patients with relapsed chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma. Clin Lymphoma 6:26-30
39. Stankiewicz A, Skrzydlewska E, Makieła M (2002) Effects of amifostine on liver oxidative stress caused by cyclophosphamide administration to rats. Drug Metabol Drug Interact 19:67-82
40. Sulkowska M, Sulkowski S (1997) The effect of pentoxifylline on ultrastructural picture of type II alveolar epithelial cells and generation of reactive oxygen species during cyclophosphamide-induced lung injury. J Submicrosc Cytol Pathol 29:487-496
41. Sulkowska M, Sulkowski S (1998) Alveolar cells in cyclophosphamide- induced lung injury. An ultrastructural analysis of type II alveolar epithelial cells in situ. Histol Histopathol 13:13-20
42. Sulkowska M, Skrzydlewska E, Sobaniec-Łotowska M et al (2002) Effect of cyclophosphamide-induced generation reactive oxygen forms on ultrastructure of the liver and lung. Bull Vet Inst Pulawy 46:239-246
43. Sundstrom S, Bremnes RM, Kaasa S, Aasebo U, Aamdal S (2005) Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen). Lung Cancer 48:251-261
44. Tannehill SP, Mehta MP (1996) Amifostine and radiation: past, present and future. Semin Oncol 23:69-77
45. Tekeoglu I, Dogan A, Demiralp L (2006) Effects of thymoquinone (volatile oil of black cumin) on rheumatoid arthritis in rat models. Phytother Res 20:869-871
46. Venkatesan N, Chandrakasan G (1995) Modulation of cyclophosphamide- induced early lung injury by curcumin, an anti-inflammatory antioxidant. Mol Cell Biochem 142:79-87
47. Vouldoukis I, Lacan D, Kamate C, Coste P, Calenda A, Mazier D, Conti M, Dugas B (2004) Antioxidant and anti-inflammatory properties of a Cucumis melo LC. extract rich in superoxide dismutase activity. J Ethnopharmacol 94:67-75
48. Woo CC, Kumar AP, Sethi G, Tan KHB (2012) Thymoquinone potential cure for inflammatory disorders and cancer. Biochem Pharmacol 83:443-451
49. Zhang J, Tian Q, Zhou S (2006) Clinical pharmacology of cyclophosphamide and ifosfamide. Current Drug Therapy 1:55-84